查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2107341

基因組編輯市場：按支付方式、基因編輯技術、基因編輯方法、基因轉移方法、基因轉移模式、最終用戶、地區和主要公司分類的趨勢和預測 - 至 2035 年

Genome Editing Market by Type of Payment Method Employed, Gene Editing Technique, Gene Editing Approach, Gene Delivery Method, Gene Delivery Modality, End-User, Geographical Regions, and Leading Industry Players - Trends and Forecast Till 2035
出版日期: | 出版商: Roots Analysis | 英文 325 Pages | 商品交期: 7-10個工作天內

價格

基因組編輯市場概覽

全球基因組編輯市場預計在預測期內（到 2035 年）將以 10.8% 的驚人複合年成長率成長，從今年的 52.9 億美元成長到 2035 年的 133.6 億美元。

基因組編輯市場 - IMG1

基因組編輯市場：成長與趨勢

基因組編輯是指一系列基因工程技術，它允許研究人員在生物體的基因組中插入、刪除或替換DNA片段。過去30年來，基因編輯領域湧現三大主要工具：鋅指核酸酶（ZFNs）、轉錄活化因子樣效應核酸酶（TALENs）和CRISPR-Cas系統。目前，CRISPR基因組編輯工具因其精確性、成本效益和易於設計等優點而被廣泛用於基因編輯。

遺傳性疾病造成的沉重全球疾病負擔及其導致的高嬰兒死亡率，大大增強了基因組編輯的臨床證據。除了疾病負擔之外，細胞治療和基因治療法律規範的日益成熟，也使得基因組編輯從單純的研究工具發展成為具有商業性可行性的治療方法。目前，已有超過1000個臨床計畫正在進行中，評估基因編輯和基因療法。

由於內部藥物研發成本高昂，以及基因編輯產品開發涉及複雜的監管流程，製藥和生物技術公司擴大選擇獲得外部基因編輯平台的授權許可，而不是自行建立工具包。這在基因組編輯價值鏈的核心形成了一種獨特的技術授權經濟模式，經銷商和通路合作夥伴在進入該領域之前必須了解這一關鍵的結構特徵。

推動成長的因素：促進全球基因組編輯市場擴張的因素

市場成長主要得益於基於 CRISPR 的細胞和基因療法的持續臨床檢驗。此外，基因組編輯標靶疾病的拓展，從單基因疾病擴展到腫瘤、神經系統疾病和代謝性疾病，以及技術開發商活性化的授權活動，都是推動市場發展的關鍵因素。向新一代鹼基編輯和先導編輯工具的過渡，能夠實現更精準的編輯並減少脫靶效應，從而拓展了該領域可標靶治療的範圍。基因組編輯在農業和診斷領域的應用不斷擴展，也推動了核心治療領域之外的成長趨勢。

市場挑戰：阻礙進展的主要障礙

儘管發展勢頭強勁，但行業相關人員仍面臨許多挑戰，阻礙市場成長。體內基因組編輯仍受免疫抗原性、脫靶效應和組織特異性不足的限制。另一方面，體外方法則面臨高成本、操作複雜等問題。此外，與CRISPR相關的智慧財產權分散化以及不斷變化的法律規範，持續為產品核可帶來授權方面的挑戰和不確定性。

基因組編輯市場區隔

市場規模和機會分析是根據以下參數進行細分的：

使用的付款方式

  • 預付款
  • 里程碑付款

透過基因編輯技術

  • CRISPR-Cas系統
  • TALEN
  • Meganucleases
  • ZFN
  • 其他技術

基因編輯方法

  • 基因敲除
  • 基因敲入

透過基因轉移方法

  • Ek Vivo
  • 體內

透過基因轉移方法

  • 病毒載體
  • 非病毒載體

透過治療方法

  • 細胞療法
  • 基因治療
  • 其他

透過使用

  • 藥物發現和藥物開發
  • 診斷

最終用戶

  • 製藥和生物技術公司
  • 學術和研究機構

按地區

  • 北美洲
  • 美國
  • 加拿大
  • 歐洲
  • 德國
  • 法國
  • 愛爾蘭
  • 亞太地區
  • 中國
  • 日本
  • 韓國

基因組編輯市場：關鍵市場區隔洞察

透過付款方式

目前，預付款模式佔據最大的市場佔有率。短期資本投資仍著重於即時取得技術和許可權，以確保擁有專有的基因組編輯平台。然而，未來隨著授權協議的成熟以及更多項目達到臨床和商業性里程碑，預計到2035年，基於里程碑付款的模式將佔據全球市場最大的佔有率。

透過基因編輯技術

CRISPR-Cas系統在技術領域佔據主導地位。其高市場佔有率歸功於該系統的多功能性，以及鹼基編輯和先導編輯等​​先進衍生技術的出現，這些技術解決了諸如準確性和脫靶效應等傳統難題。尤其值得一提的是，預計該領域將在預測期內持續保持成長勢頭，並實現較高的複合年成長率。

該平台憑藉其固有的多功能性和快速的結構改進，保持了其市場主導地位。新一代工具，特別是鹼基編輯和先導編輯，緩解了早期安全性和準確性方面的挑戰，例如脫靶切割和雙鏈DNA斷裂，從而鞏固了CRISPR作為主要臨床標準的地位。

基因編輯方法

基因敲除技術在全球市場佔最大佔有率。其高佔有率源自於基因敲除技術相比基因敲入策略更為簡便，後者需要更複雜的最佳化才能實現精確的序列插入。

透過基因轉移方法

體外（體外）遞送方法佔據最大的市場佔有率。這項優勢主要源自於體外細胞修飾相比體內（體內）遞送方法，能夠實現更嚴格的品管並降低脫靶風險。在體外基因組編輯中，首先分離患者來源的細胞，在受控的實驗室條件下進行基因修飾，然後在重新注射回患者體內之前，對編輯效率和安全性進行嚴格的測試。

這種方法能夠實現精準的品管，最大限度地減少脫靶編輯，並降低基因組編輯成分的全身暴露，從而提高整體安全性。此外，體外遞送非常適合針對造血幹細胞和免疫細胞的 CRISPR-Cas、TALEN 和鋅指核酸酶療法，這些療法已顯示出令人鼓舞的臨床療效。

透過基因轉移方法

由於病毒載體具有基因轉移效率高、基因轉殖表達穩定以及經過廣泛的臨床檢驗等優點，目前在基因組編輯市場中佔據最大佔有率。腺結合病毒（AAV）、慢病毒載體和腺病毒載體等遞送平台廣泛應用於臨床試驗和已通過核准的基因及細胞療法，尤其是在體外應用中。成熟的生產流程、經過充分評估的安全性以及對監管法規的了解進一步鞏固了其市場地位。

然而，預計在預測期內，非病毒遞送方法將呈現最高的複合年成長率。這一轉變是由對更安全、更具可擴展性和成本效益的遞送平台的需求不斷成長所驅動的。脂質奈米顆粒（LNP）、聚合物奈米顆粒、電穿孔和其他物理遞送方法等技術因其消除了插入突變風險、降低了免疫抗原性並可重複給藥，而特別適用於體內基因組編輯應用。

透過治療方法

細胞療法是主要應用領域之一，佔據最大的市場佔有率。如此高的市場佔有率反映了其在多種疾病領域的廣泛效用。基因編輯細胞療法，特別是CAR-T、TCR-T和造血幹細胞療法，已取得顯著的臨床成功，這得益於「體外編輯」技術的應用，該技術能夠實現精準的基因修飾、嚴格的品管和更高的安全性。自體和異體細胞療法的研發管線不斷擴展，加上監管部門批准數量的增加、生產製造方面的投資以及戰略合作的推進，持續鞏固該領域在市場上的主導地位。

同時，針對罕見疾病和單基因疾病的基因療法預計在預測期內將保持較高的複合年成長率。這一成長主要得益於基於 CRISPR 技術、鹼基編輯、先導編輯和基於 mRNA 的基因組編輯技術的快速發展，這些技術正在將治療範圍從罕見單基因疾病擴展到更常見的遺傳性疾病、代謝性疾病、眼科疾病、心血管疾病和神經系統疾病。

透過使用

藥物發現和開發是推動市場發展的主要動力。其中，利用基於 CRISPR 的篩檢來識別新型藥物標靶佔據了最大的市場佔有率。同時，目前規模較小的診斷應用，隨著基因組編輯工具在疾病早期檢測中的應用，預計在預測期內將以較高的複合年成長率 (CAGR) 成長。

最終用戶

這與製藥和生物技術公司佔據最大市場佔有率的事實相符，並且該領域約 90% 的技術許可和整合協議都是與私人公司而不是學術機構簽訂的。

北美市佔率最大，而亞太地區的複合年成長率較高。

我們的預測表明，北美在全球市場中處於領先地位，並有望在未來繼續保持其主導地位。這一成長主要得益於技術開發公司的集中、數量最多的授權交易以及該領域獲得的最大規模的創業投資投資和機構投資者資金。

基因組編輯市場主要公司範例

  • Arcturus Therapeutics
  • ArsenalBio
  • Avectas
  • Beam Therapeutics
  • Bio-Sourcing
  • Caribou Biosciences
  • Century Therapeutics
  • CRISPR Therapeutics
  • Editas Medicine
  • Flash BioSolutions
  • Graphite Bio
  • Intellia Therapeutics
  • NTrans Technologies
  • OXGENE
  • Prime Medicine
  • Revvity
  • Vor Biopharma

專家訪談與業界考察

本研究提出的觀點和見解是基於與多位相關人員的討論。本報告包含與以下行業相關人員的詳細訪談記錄：

  • 美國某大型機構的執行長
  • 美國一家中型公司的首席科學官
  • 一家歐洲大型公司的技術長(CTO)
  • 美國大型企業業務拓展副總裁
  • 亞太地區的學術機構和研究領導人物。
  • 美國一家中型機構的首席醫療官

基因組編輯市場：研究範圍

  • 市場規模和機會分析：對基因組編輯市場規模和預測進行詳細分析，涵蓋關鍵細分市場，包括使用的支付方式類型、基因編輯技術類型、基因編輯方法、基因轉移方法類型、基因轉移模式、治療類型、應用領域、最終用戶類型和地區。
  • 技術與研發公司趨勢：本報告詳細評估了目前基因組編輯技術的發展趨勢，並按基因編輯技術類型、基因編輯方法、基因遞送方式、基因遞送模式、支援的最高研發階段、治療領域和應用領域進行分類。此外，報告還根據技術提供者的成立年份、公司規模、總部所在地和商業模式對其進行了分析。
  • 企業競爭分析：這份深入的競爭分析報告聚焦於基因組編輯技術提供者。它根據各公司的優勢和技術能力進行基準分析，並將它們分為總部位於北美、歐洲和亞太地區的競爭對手群體。
  • 公司簡介：詳細介紹北美、歐洲和亞太地區領先的基因組編輯技術開發公司。每家公司的簡介都包含公司概況、技術組合、近期發展以及對未來的展望。
  • 合作與聯合研究分析：這是對自 2018 年以來基因組編輯技術提供者之間的合作活動進行的全面分析，按年份、合作類型、重點領域、地區和最活躍的公司進行評估。
  • 專利分析：這包括對自 2018 年以來基因組編輯技術提供者的專利申請和已授權專利進行詳細分析，按公佈年份、地區、CPC 分類和申請人類型進行評估，以及專利基準、評估和引用分析。
  • 資金籌措和投資分析：對 2018 年以來基因組編輯技術提供者的資金籌措和投資活動進行全面評估，按年份、資金籌措類型、投資金額、地區以及最活躍的參與者和投資者進行評估。
  • 市場影響分析：對影響基因組編輯市場成長的促進因素、阻礙因素、機會與挑戰進行詳細分析。

目錄

第1章 背景

第2章：調查方法

第3章 市場動態

第4章 宏觀經濟指標

第5章執行摘要

第6章：引言

第7章 市場趨勢：基因組編輯技術

第8章：技術競爭力分析

第9章 基因組編輯市場：北美領導者簡介

  • 章節概要
  • Arcturus Therapeutics
  • Arsenal Bio
  • Beam Therapeutics
  • Caribou Biosciences
  • Century Therapeutics
  • CRISPR Therapeutics
  • Editas Medicine
  • Intellia Therapeutics
  • Prime Medicine
  • Vor Biopharma

第10章 基因組編輯市場：歐洲領導公司簡介

  • 章節概要
  • Avectas
  • Bio-Sourcing
  • Flash Therapeutics
  • NTrans Technologies
  • OXGENE（Acquired by WuXi AppTec）
  • Revvity（formerly known as Horizon Discovery）

第11章 基因組編輯市場：亞太及世界其他地區領導企業的公司簡介

  • 章節概要
  • Edigene
  • Fortgen
  • G+FLAS Life Sciences
  • TargetGene Biotechnologies

第12章夥伴關係與合作

第13章 專利分析

第14章資金籌措與投資分析

第15章 市場影響分析：促進因素、阻礙因素、機會與挑戰

第16章：基因組編輯技術市場

第17章：基因組編輯技術市場（以支付方式分類）

第18章：基因組編輯技術市場（依基因編輯技術分類）

第19章：基因組編輯技術市場（以基因編輯方法分類）

第20章：基因組編輯技術市場（以基因轉殖方法分類）

第21章：基因組編輯技術市場（依基因轉殖方法分類）

第22章：基因組編輯技術市場（依治療方法分類）

第23章：基因組編輯技術市場（按應用領域分類）

第24章：基因組編輯技術市場（依最終用戶分類）

第25章：基因組編輯技術市場（按主要地區分類）

第26章 基因組編輯技術市場：主要產業參與企業

第27章 結論

第28章：高階主管洞察

第29章附錄1：表格形式數據

第30章 附錄2：公司與組織列表

Product Code: RA100464

GENOME EDITING MARKET: OVERVIEW

As per Roots Analysis, the global genome editing market is estimated to grow from USD 5.29 billion in the current year to USD 13.36 billion by 2035, at an impressive CAGR of 10.8%, during the forecast period, till 2035.

Genome Editing Market - IMG1

Genome Editing Market: Growth and Trends

Genome editing refers to a set of genetic engineering techniques that allow researchers to insert, delete, or replace segments of DNA within the genome of an organism. Three broad classes of tools have emerged in gene editing over the past three decades namely, zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and the CRISPR-Cas system. Presently, CRISPR genome editing tool is widely used for gene editing owing to its precision, cost efficiency, and ease of design.

The clinical rationale for genome editing has strengthened significantly, driven by the substantial global burden of genetic disorders and the significant contribution of inherited genetic conditions to infant mortality. This disease burden, combined with maturing regulatory pathways for cell and gene therapies, has pushed genome editing from a research tool into a commercially viable therapeutic modality. Presently, over a thousand active clinical programs are currently evaluating gene-edited and gene-based interventions.

Pharmaceutical and biotechnology companies are increasingly licensing external editing platforms rather than building proprietary toolkits due to the high expense of in-house discovery and the regulatory complexity of gene-edited product development. This has created a distinct technology-licensing economy that sits at the center of the genome editing value chain and is a key structural feature distributors and channel partners should understand before entering this space.

Growth Drivers: Factors Fueling Expansion of the Global Genome Editing Market

Market growth is being driven by the steady clinical validation of CRISPR-based cell and gene therapies. Further, the expanding disease scope of genome editing beyond monogenic disorders into oncology, neurology and metabolic disease, and rising out-licensing activity among technology originators are the key drivers of the market. The transition toward next-generation base and prime editing tools, which offer more precise edits with fewer off-target effects, is widening the addressable therapeutic scope of the field. Growing agricultural and diagnostic applications of genome editing are reinforcing this trajectory outside of core therapeutics.

Market Challenges: Critical Barriers Hindering Progress

Despite strong momentum, the industry players are witnessing several challenges that impede market growth. In vivo genome editing remains limited by immunogenicity, off-target effects, and inadequate tissue specificity. On the other hand, ex vivo approaches are hindered by high costs and operational complexity. Additionally, fragmented CRISPR intellectual property and evolving regulatory frameworks continue to create licensing challenges and uncertainty around product approvals.

Genome Editing Market Segments

The market sizing and opportunity analysis has been segmented across the following parameters:

By Type of Payment Method Employed

  • Upfront Payments
  • Milestone Payments

By Type of Gene Editing Technique

  • CRISPR-Cas System
  • TALENs
  • Meganucleases
  • ZFNs
  • Other Techniques

By Gene Editing Approach

  • Gene Knock-Out
  • Gene Knock-In

By Type of Gene Delivery Method

  • Ex Vivo
  • In Vivo

By Gene Delivery Modality

  • Viral Vectors
  • Non-Viral Vectors

By Type of Therapy

  • Cell Therapies
  • Gene Therapies
  • Other Therapies

By Application Area

  • Drug Discovery and Development
  • Diagnostics

By Type of End-User

  • Pharmaceutical and Biotechnology Companies
  • Academic and Research Institutes

By Geographical Regions

  • North America
  • US
  • Canada
  • Europe
  • Germany
  • France
  • Ireland
  • Asia-Pacific
  • China
  • Japan
  • South Korea

Genome Editing Market: Key Segmentation Insights

By Payment Method

Upfront payments currently account for the largest share of the market. Capital commitment in the short term remains heavily weighted toward immediate technology acquisition and licensing rights to secure proprietary genome editing platforms. However, in the future, milestone-based payments segment is projected to hold the highest global market share by 2035 as licensing deals mature and more programs advance through clinical and commercial milestones.

By Gene Editing Technique

CRISPR-Cas systems dominate the technology landscape. This highest share is due to the versatility of the system and the emergence of refined variants such as base and prime editing that address earlier limitations around precision and off-target effects. Notably, this segment will continue to gain momentum, anticipated to register higher CAGR during the forecast period.

Market leadership is sustained by the platform's inherent versatility and rapid structural refinements. Next-generation tools specifically base editing and prime editing are mitigating early safety and accuracy challenges like off-target cleavage and double-stranded DNA breaks, solidifying CRISPR's position as the primary clinical standard.

By Gene Editing Approach

Gene knock-out approaches hold the largest share of the global market. This highest share is due to their relative technical simplicity compared with knock-in strategies, which require more complex optimization to achieve precise sequence insertion.

By Gene Delivery Method

Ex vivo delivery leads by holding highest share of the market. This dominance is largely because modifying cells outside the body allows tighter quality control and lower off-target risk than in vivo delivery. In ex vivo genome editing, patient-derived cells are isolated, genetically modified under controlled laboratory conditions, rigorously tested for editing efficiency and safety, and then reinfused into the patient.

This approach enables precise quality control, minimizes off-target editing, and reduces systemic exposure to genome editing components, thereby improving the overall safety profile. Furthermore, ex vivo delivery is well suited for CRISPR-Cas, TALEN, and zinc finger nuclease-based therapies targeting hematopoietic stem cells and immune cells, which have demonstrated encouraging clinical outcomes.

By Gene Delivery Modality

Viral vectors currently account for the largest share of the genome editing market, owing to their high gene transfer efficiency, robust transgene expression, and extensive clinical validation. Delivery platforms such as adeno-associated viruses (AAVs), lentiviral vectors, and adenoviral vectors are widely used in both clinical trials and approved gene and cell therapies, particularly for ex vivo applications. Their established manufacturing processes, well-characterized safety profiles, and regulatory familiarity have further strengthened their market position.

However, non-viral delivery modalities are expected to witness the fastest CAGR during the forecast period. This shift is driven by increasing demand for safer, more scalable, and cost-effective delivery platforms. Technologies such as lipid nanoparticles (LNPs), polymer-based nanoparticles, electroporation, and other physical delivery methods eliminate the risk of insertional mutagenesis, reduce immunogenicity, and enable repeat dosing, making them particularly attractive for in vivo genome editing applications.

.

By Type of Therapy

Cell therapies represent the leading application by holding the highest share. This highest share reflects their broad utility across multiple disease areas. Genome-edited cell therapies, particularly CAR-T, TCR-T, and hematopoietic stem cell-based therapies, have demonstrated significant clinical success and benefit from the use of ex vivo editing, which enables precise genetic modification, stringent quality control, and improved safety. The expanding pipeline of autologous and allogeneic cell therapies, coupled with increasing regulatory approvals, manufacturing investments, and strategic collaborations, continues to strengthen the segment's market leadership.

On the other hand, gene therapy, which is more narrowly focused on rare and monogenic conditions, is expected to grow at a higher CAGR during the forecast period. This growth is driven by the rapid advancement of CRISPR-based, base editing, prime editing, and mRNA-enabled genome editing technologies, which are expanding therapeutic opportunities beyond rare monogenic disorders to include more prevalent genetic, metabolic, ophthalmic, cardiovascular, and neurological diseases.

By Application Area

Drug discovery and development dominate the market. This highest share is driven by the use of CRISPR-based screening to identify novel drug targets. Conversely, diagnostic applications, while smaller today, are expected to expand at a higher CAGR during the forecast period as genome editing tools are adapted for early disease detection.

By End User

Pharmaceutical and biotechnology companies capture the highest share of the market, consistent with the fact that roughly 90% of technology licensing and integration agreements in this space are inked with commercial rather than academic entities.

North America Holds the Highest Share and Asia-Pacific Grows at Higher CAGR

According to our projections, North America leads the global market and is likely to remain dominant in the future. This growth is underpinned by the concentration of technology developers, the highest volume of licensing transactions and the largest pool of venture and institutional capital directed toward the sector.

Example Players in Genome Editing Market

  • Arcturus Therapeutics
  • ArsenalBio
  • Avectas
  • Beam Therapeutics
  • Bio-Sourcing
  • Caribou Biosciences
  • Century Therapeutics
  • CRISPR Therapeutics
  • Editas Medicine
  • Flash BioSolutions
  • Graphite Bio
  • Intellia Therapeutics
  • NTrans Technologies
  • OXGENE
  • Prime Medicine
  • Revvity
  • Vor Biopharma

Expert Interview and Industry Insights

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:

  • Chief Executive Officer, Large Organization, US
  • Chief Scientific Officer, Mid-Sized Organization, US
  • Chief Technology Officer, Large Organization, Europe
  • Vice President, Business Development, Large Organization, US
  • Head of Research, Academic Institute, Asia-Pacific
  • Chief Medical Officer, Mid-Sized Organization, US

GENOME EDITING MARKET: RESEARCH COVERAGE

  • Market Sizing and Opportunity Analysis: An in-depth analysis of the genome editing market size and forecast across key segments, including type of payment method employed, type of gene editing technique, gene editing approach, type of gene delivery method, gene delivery modality, type of therapy, application area, type of end-user and geography.
  • Technology and Developer Landscape: A detailed assessment of the current technology landscape for genome editing, evaluated by type of gene editing technique, gene editing approach, gene delivery method, gene delivery modality, highest phase of development supported, therapeutic area and application area, along with an analysis of technology providers by year of establishment, company size, location of headquarters and operating model.
  • Company Competitiveness Analysis: An insightful competitiveness analysis of genome editing technology providers, benchmarked on company strength and technology strength, segmented across peer groups headquartered in North America, Europe, and Asia-Pacific.
  • Company Profiles: Elaborate and short profiles of prominent players developing genome editing technologies across North America, Europe and Asia-Pacific, featuring company overview, technology portfolio, recent developments, and an informed future outlook.
  • Partnerships and Collaborations Analysis: A comprehensive assessment of partnership activity among genome editing technology providers since 2018, evaluated by year, type of partnership, focus area, geography, and most active players.
  • Patent Analysis: An in-depth analysis of patents filed and granted to genome editing technology providers since 2018, evaluated by publication year, geography, CPC classification, and applicant type, along with patent benchmarking, valuation, and citation analysis.
  • Funding and Investment Analysis: A comprehensive assessment of funding and investment activity among genome editing technology providers since 2018, evaluated by year, type of funding, amount invested, geography, and most active players and investors.
  • Market Impact Analysis: An in-depth analysis of the drivers, restraints, opportunities, and challenges influencing the growth of the genome editing market.

Key Questions Answered in this Report

  • How large is the genome editing market today, and how large will it be by 2035?
  • Which gene editing techniques, delivery methods and delivery modalities are gaining or losing share?
  • Which companies are best positioned across each segment, and how deep is their technology and pipeline portfolio?
  • How is the balance between upfront and milestone-based licensing likely to evolve?
  • Which application areas beyond drug discovery offer the strongest medium-term upside?
  • Which geographies offer the best combination of near-term revenue and long-term growth rate?

Reasons to Buy this Report

Distributors evaluating the genome editing opportunity need more than a headline market size figure. This report is built to support commercial decision-making, not just awareness, and differentiates itself on the following counts:

  • Top-Down and Bottom-Up Triangulated Forecasting: Revenue projections for each segment are cross-validated using both technology-adoption trends and company-level deal data, reducing forecast risk for investors and channel partners.
  • Primary Research: Insights are grounded in interviews with CEOs, chief scientific officers, and business development leaders across large, mid-sized and academic organizations, not desk research alone.
  • Investor-Grade Financial Context: Company profiles include funding history, recent capital deployment and partnership activity, positioned for use in diligence and business case development.
  • Patent and IP Landscape Clarity: A dedicated patent benchmarking chapter helps distributors and licensees navigate the fragmented CRISPR intellectual property landscape before entering supply or distribution agreements.

Additional Benefits

  • Complementary Insights Pack
  • 15% Free Content Customization
  • Detailed Report Walkthrough Session with Research Team
  • Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. BACKGROUND

  • 1.1. Context
  • 1.2. Project Objectives

2. RESEARCH METHODOLOGY

  • 2.1. Chapter Overview
  • 2.2. Research Assumptions
    • 2.2.1. Market Landscape and Market Trends
    • 2.2.2. Market Forecast and Opportunity Analysis
    • 2.2.3. Comparative Analysis
  • 2.3. Database Building
    • 2.3.1. Data Collection
    • 2.3.2. Data Validation
    • 2.3.3. Data Analysis
  • 2.4. Project Methodology
    • 2.4.1. Secondary Research
      • 2.4.1.1. Annual Reports
      • 2.4.1.2. Academic Research Papers
      • 2.4.1.3. Company Websites
      • 2.4.1.4. Investor Presentations
      • 2.4.1.5. Regulatory Filings
      • 2.4.1.6. White Papers
      • 2.4.1.7. Industry Publications
      • 2.4.1.8. Conferences and Seminars
      • 2.4.1.9. Government Portals
      • 2.4.1.10. Media and Press Releases
      • 2.4.1.11. Newsletters
      • 2.4.1.12. Industry Databases
      • 2.4.1.13. Roots Proprietary Databases
      • 2.4.1.14. Paid Databases and Sources
      • 2.4.1.15. Social Media Portals
      • 2.4.1.16. Other Secondary Sources
    • 2.4.2. Primary Research
      • 2.4.2.1. Types of Primary Research
        • 2.4.2.1.1. Qualitative Research
        • 2.4.2.1.2. Quantitative Research
        • 2.4.2.1.3. Hybrid Approach
      • 2.4.2.2. Advantages of Primary Research
      • 2.4.2.3. Techniques for Primary Research
        • 2.4.2.3.1. Interviews
        • 2.4.2.3.2. Surveys
        • 2.4.2.3.3. Focus Groups
        • 2.4.2.3.4. Observational Research
        • 2.4.2.3.5. Social Media Interactions
      • 2.4.2.4. Key Opinion Leaders Considered in Primary Research
        • 2.4.2.4.1. Company Executives (CXOs)
        • 2.4.2.4.2. Board of Directors
        • 2.4.2.4.3. Company Presidents and Vice Presidents
        • 2.4.2.4.4. Research and Development Heads
        • 2.4.2.4.5. Technical Experts
        • 2.4.2.4.6. Subject Matter Experts
        • 2.4.2.4.7. Scientists
        • 2.4.2.4.8. Doctors and Other Healthcare Providers
      • 2.4.2.5. Ethics and Integrity
        • 2.4.2.5.1. Research Ethics
        • 2.4.2.5.2. Data Integrity
    • 2.4.3. Analytical Tools and Databases
  • 2.5. Robust Quality Control

3. MARKET DYNAMICS

  • 3.1. Chapter Overview
  • 3.2. Forecast Methodology
    • 3.2.1. Top-down Approach
    • 3.2.2. Bottom-up Approach
    • 3.2.3. Hybrid Approach
  • 3.3. Market Assessment Framework
    • 3.3.1. Total Addressable Market (TAM)
    • 3.3.2. Serviceable Addressable Market (SAM)
    • 3.3.3. Serviceable Obtainable Market (SOM)
    • 3.3.4. Currently Acquired Market (CAM)
  • 3.4. Forecasting Tools and Techniques
    • 3.4.1. Qualitative Forecasting
    • 3.4.2. Correlation
    • 3.4.3. Regression
    • 3.4.4. Extrapolation
    • 3.4.5. Convergence
    • 3.4.6. Sensitivity Analysis
    • 3.4.7. Scenario Planning
    • 3.4.8. Data Visualization
    • 3.4.9. Time Series Analysis
    • 3.4.10. Forecast Error Analysis
  • 3.5. Key Considerations
    • 3.5.1. Demographics
    • 3.5.2. Government Regulations
    • 3.5.3. Reimbursement Scenarios
    • 3.5.4. Market Access
    • 3.5.5. Supply Chain
    • 3.5.6. Industry Consolidation
    • 3.5.7. Pandemic / Unforeseen Disruptions Impact
  • 3.6. Limitations

4. MACRO-ECONOMIC INDICATORS

  • 4.1. Chapter Overview
  • 4.2. Market Dynamics
    • 4.2.1. Time Period
      • 4.2.1.1. Historical Trends
      • 4.2.1.2. Current and Forecasted Estimates
    • 4.2.2. Currency Coverage
      • 4.2.2.1. Major Currencies Affecting the Market
      • 4.2.2.2. Factors Affecting Currency Fluctuations on the Industry
      • 4.2.2.3. Impact of Currency Fluctuations on the Industry
    • 4.2.3. Foreign Currency Exchange Rate
      • 4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
      • 4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
    • 4.2.4. Recession
      • 4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
      • 4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
    • 4.2.5. Inflation
      • 4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
      • 4.2.5.2. Potential Impact of Inflation on the Market Evolution
    • 4.2.6. Interest Rates
      • 4.2.6.1. Interest Rates and Their Impact on the Market
      • 4.2.6.2. Strategies for Managing Interest Rate Risk
    • 4.2.7. Commodity Flow Analysis
      • 4.2.7.1. Type of Commodity
      • 4.2.7.2. Origins and Destinations
      • 4.2.7.3. Values and Weights
      • 4.2.7.4. Modes of Transportation
    • 4.2.8. Global Trade Dynamics
      • 4.2.8.1. Import Scenario
      • 4.2.8.2. Export Scenario
      • 4.2.8.3. Trade Policies
      • 4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
      • 4.2.8.5. Impact of Trade Barriers on the Market
    • 4.2.9. War Impact Analysis
      • 4.2.9.1. Russian-Ukraine War
      • 4.2.9.2. Israel-Hamas War
    • 4.2.10. COVID Impact / Related Factors
      • 4.2.10.1. Global Economic Impact
      • 4.2.10.2. Industry-specific Impact
      • 4.2.10.3. Government Response and Stimulus Measures
      • 4.2.10.4. Future Outlook and Adaptation Strategies
    • 4.2.11. Other Indicators
      • 4.2.11.1. Fiscal Policy
      • 4.2.11.2. Consumer Spending
      • 4.2.11.3. Gross Domestic Product
      • 4.2.11.4. Employment
      • 4.2.11.5. Taxes
      • 4.2.11.6. Stock Market Performance
      • 4.2.11.7. Cross Border Dynamics
  • 4.3. Conclusion

5. EXECUTIVE SUMMARY

6. INTRODUCTION

  • 6.1. Chapter Overview
  • 6.2. Introduction to Gene Editing
    • 6.2.1. Evolution of Gene Editing
    • 6.2.2. Gene Editing Technologies
      • 6.2.2.1. CRISPR - CAS System
      • 6.2.2.2. Transcription Activator-Like Effector Nucleases (TALENs)
      • 6.2.2.3. Zinc Finger Nucleases (ZFNs)
      • 6.2.2.4. Meganucleases / Homing Endonucleases
  • 6.3. Applications of Genome Editing Technologies
  • 6.4. Other Emerging Technologies
  • 6.5. Concluding Remarks

7. MARKET LANDSCAPE: GENOME EDITING TECHNOLOGIES

  • 7.1. Chapter Overview
  • 7.2. Genome Editing: Technology Landscape
    • 7.2.1. Analysis by Type of Gene Editing Technique
    • 7.2.2. Analysis by Type of Gene Editing Approach
    • 7.2.3. Analysis by Type of Gene Delivery Method
    • 7.2.4. Analysis by Type of Gene Delivery Modality
    • 7.2.5. Analysis by Highest Phase of Drug Development Supported
    • 7.2.6. Analysis by Therapeutic Area
    • 7.2.7. Analysis by Application Area
  • 7.3. Genome Editing: Technology Providers Landscape
    • 7.3.1. Analysis by Year of Establishment
    • 7.3.2. Analysis by Company Size
    • 7.3.3. Analysis by Location of Headquarters
    • 7.3.4. Analysis by Company Size and Location of Headquarters
    • 7.3.5. Most Active Players: Analysis by Number of Technologies
    • 7.3.6. Analysis by Operational Model

8. TECHNOLOGY COMPETITIVENESS ANALYSIS

  • 8.1. Chapter Overview
  • 8.2. Assumptions / Key Parameters
  • 8.3. Methodology
  • 8.4. Technology Competitiveness Analysis
    • 8.4.1. Genome Editing Technologies Offered by Players Headquartered in North America
    • 8.4.2. Genome Editing Technologies Offered by Players Headquartered in Europe
    • 8.4.3. Genome Editing Technologies Offered by Players Headquartered in Asia-Pacific, Middle East and North Africa, and Latin America

9. GENOME EDITING MARKET: COMPANY PROFILES OF PLAYERS BASED IN NORTH AMERICA

  • 9.1. Chapter Overview
  • 9.2. Arcturus Therapeutics
    • 9.2.1. Company Overview
    • 9.2.2. Financial Information
    • 9.2.3. Technology Portfolio
    • 9.2.4. Recent Developments and Future Outlook
  • 9.3. Arsenal Bio
    • 9.3.1. Company Overview
    • 9.3.2. Technology Portfolio
    • 9.3.3. Recent Developments and Future Outlook
  • 9.4. Beam Therapeutics
    • 9.4.1. Company Overview
    • 9.4.2. Financial Information
    • 9.4.3. Technology Portfolio
    • 9.4.4. Recent Developments and Future Outlook
  • 9.5. Caribou Biosciences
    • 9.5.1. Company Overview
    • 9.5.2. Financial Information
    • 9.5.3. Technology Portfolio
    • 9.5.4. Recent Developments and Future Outlook
  • 9.6. Century Therapeutics
    • 9.6.1. Company Overview
    • 9.6.2. Financial Information
    • 9.6.3. Technology Portfolio
    • 9.6.4. Recent Developments and Future Outlook
  • 9.7. CRISPR Therapeutics
    • 9.7.1. Company Overview
    • 9.7.2. Financial Information
    • 9.7.3. Technology Portfolio
    • 9.7.4. Recent Developments and Future Outlook
  • 9.8. Editas Medicine
    • 9.8.1. Company Overview
    • 9.8.2. Financial Information
    • 9.8.3. Technology Portfolio
    • 9.8.4. Recent Developments and Future Outlook
  • 9.9. Intellia Therapeutics
    • 9.9.1. Company Overview
    • 9.9.2. Financial Information
    • 9.9.3. Technology Portfolio
    • 9.9.4. Recent Developments and Future Outlook
  • 9.10. Prime Medicine
    • 9.10.1. Company Overview
    • 9.10.2. Technology Portfolio
    • 9.10.3. Recent Developments and Future Outlook
  • 9.11. Vor Biopharma
    • 9.11.1. Company Overview
    • 9.11.2. Technology Portfolio
    • 9.11.3. Recent Developments and Future Outlook

10. GENOME EDITING MARKET: COMPANY PROFILES OF PLAYERS BASED IN EUROPE

  • 10.1. Chapter Overview
  • 10.2. Avectas
    • 10.2.1. Company Overview
    • 10.2.2. Technology Portfolio
  • 10.3. Bio-Sourcing
    • 10.3.1. Company Overview
    • 10.3.2. Technology Portfolio
  • 10.4. Flash Therapeutics
    • 10.4.1. Company Overview
    • 10.4.2. Technology Portfolio
  • 10.5. NTrans Technologies
    • 10.5.1. Company Overview
    • 10.5.2. Technology Portfolio
  • 10.6. OXGENE (Acquired by WuXi AppTec)
    • 10.6.1. Company Overview
    • 10.6.2. Technology Portfolio
  • 10.7. Revvity (formerly known as Horizon Discovery)
    • 10.7.1. Company Overview
    • 10.7.2. Technology Portfolio

11. GENOME EDITING MARKET: COMPANY PROFILES OF PLAYERS BASED IN ASIA-PACIFIC AND REST OF THE WORLD

  • 11.1. Chapter Overview
  • 11.2. Edigene
    • 11.2.1. Company Overview
    • 11.2.2. Technology Portfolio
  • 11.3. Fortgen
    • 11.3.1. Company Overview
    • 11.3.2. Technology Portfolio
  • 11.4. G+FLAS Life Sciences
    • 11.4.1. Company Overview
    • 11.4.2. Technology Portfolio
  • 11.5. TargetGene Biotechnologies
    • 11.5.1. Company Overview
    • 11.5.2. Technology Portfolio

12. PARTNERSHIPS AND COLLABORATIONS

  • 12.1. Chapter Overview
  • 12.2. Partnership Models
  • 12.3. Genome Editing Technologies: Partnerships and Collaborations
    • 12.3.1. Analysis by Year of Partnership
    • 12.3.2. Analysis by Type of Partnership
    • 12.3.3. Analysis by Year and Type of Partnership
    • 12.3.4. Analysis by Purpose of Partnership
    • 12.3.5. Analysis by Type of Partner
    • 12.3.6. Analysis by Location of Headquarters of Partner
    • 12.3.7. Most Active Players: Analysis by Number of Partnerships
    • 12.3.8. Analysis by Geography
      • 12.3.8.1. Local and International Agreements
      • 12.3.8.2. Intercontinental and Intracontinental Agreements

13. PATENT ANALYSIS

  • 13.1. Chapter Overview
  • 13.2. Scope and Methodology
  • 13.3. Genome Editing Domain: Patent Analysis
    • 13.3.1. Analysis by Publication Year
    • 13.3.2. Analysis by Type of Patent and Publication Year
    • 13.3.3. Analysis by Geography
    • 13.3.4. Analysis by CPC Symbols
    • 13.3.5. Leading Industry Players: Analysis by Number of Patents
  • 13.4. Genome Editing Domain: Patent Benchmarking Analysis
    • 13.4.1. Analysis by Patent Characteristics
    • 13.4.2. Analysis by Leading Industry Players
  • 13.5. Patent Valuation Analysis

14. FUNDING AND INVESTMENT ANALYSIS

  • 14.1. Chapter Overview
  • 14.2. Funding Models
  • 14.3. Genome Editing Market: Funding and Investment Analysis
    • 14.3.1. Analysis by Year of Funding
      • 14.3.1.1. Cumulative Year-wise Trend of Funding Instances
      • 14.3.1.2. Cumulative Year-wise Trend of Amount Invested
    • 14.3.2. Analysis by Type of Funding
      • 14.3.2.1. Analysis by Funding Instances
      • 14.3.2.2. Analysis by Amount Invested
    • 14.3.3. Analysis by Year and Type of Funding
    • 14.3.4. Analysis by Geography
    • 14.3.5. Most Active Players: Analysis by Amount Invested and Number of Funding Instances
    • 14.3.6. Leading Investors: Analysis by Number of Funding Instances
  • 14.4. Concluding Remarks

15. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

  • 15.1. Chapter Overview
  • 15.2. Market Drivers
  • 15.3. Market Restraints
  • 15.4. Market Opportunities
  • 15.5. Market Challenges
  • 15.6. Conclusion

16. GENOME EDITING TECHNOLOGIES MARKET

  • 16.1. Chapter Overview
  • 16.2. Assumptions and Methodology
  • 16.3. Genome Editing Technologies Market: Forecasted Estimates, till 2035
    • 16.3.1. Scenario Analysis
      • 16.3.1.1. Conservative Scenario
      • 16.3.1.2. Optimistic Scenario
  • 16.4. Key Market Segmentations

17. GENOME EDITING TECHNOLOGIES MARKET, BY TYPE OF PAYMENT METHOD EMPLOYED

  • 17.1. Chapter Overview
  • 17.2. Key Assumptions and Methodology
  • 17.3. Genome Editing Technologies Market: Distribution by Type of Payment Method Employed
    • 17.3.1. Genome Editing Technologies Market for Milestone Payments: Forecasted Estimates, till 2035
    • 17.3.2. Genome Editing Technologies Market for Upfront Payments: Forecasted Estimates, till 2035
  • 17.4. Data Triangulation

18. GENOME EDITING TECHNOLOGIES MARKET, BY TYPE OF GENE EDITING TECHNIQUE

  • 18.1. Chapter Overview
  • 18.2. Key Assumptions and Methodology
  • 18.3. Genome Editing Technologies Market: Distribution by Type of Gene Editing Technique
    • 18.3.1. Genome Editing Technologies Market for CRISPR-Cas System: Forecasted Estimates, till 2035
    • 18.3.2. Genome Editing Technologies Market for TALENs: Forecasted Estimates, till 2035
    • 18.3.3. Genome Editing Technologies Market for Meganucleases: Forecasted Estimates, till 2035
    • 18.3.4. Genome Editing Technologies Market for ZFNs: Forecasted Estimates, till 2035
    • 18.3.5. Genome Editing Technologies Market for Other Techniques: Forecasted Estimates, till 2035
  • 18.4. Data Triangulation

19. GENOME EDITING TECHNOLOGIES MARKET, BY GENE EDITING APPROACH

  • 19.1. Chapter Overview
  • 19.2. Key Assumptions and Methodology
  • 19.3. Genome Editing Technologies Market: Distribution by Gene Editing Approach
    • 19.3.1. Genome Editing Technologies Market for Gene Knock-Out Approaches: Forecasted Estimates, till 2035
    • 19.3.2. Genome Editing Technologies Market for Gene Knock-In Approaches: Forecasted Estimates, till 2035
  • 19.4. Data Triangulation

20. GENOME EDITING TECHNOLOGIES MARKET, BY GENE DELIVERY METHOD

  • 20.1. Chapter Overview
  • 20.2. Key Assumptions and Methodology
  • 20.3. Genome Editing Technologies Market: Distribution by Gene Delivery Method
    • 20.3.1. Genome Editing Technologies Market for Ex Vivo Delivery Methods: Forecasted Estimates, till 2035
    • 20.3.2. Genome Editing Technologies Market for In Vivo Delivery Methods: Forecasted Estimates, till 2035
  • 20.4. Data Triangulation

21. GENOME EDITING TECHNOLOGIES MARKET, BY GENE DELIVERY MODALITY

  • 21.1. Chapter Overview
  • 21.2. Key Assumptions and Methodology
  • 21.3. Genome Editing Technologies Market: Distribution by Gene Delivery Modality
    • 21.3.1. Genome Editing Technologies Market for Viral Vectors: Forecasted Estimates, till 2035
    • 21.3.2. Genome Editing Technologies Market for Non-Viral Vectors: Forecasted Estimates, till 2035
  • 21.4. Data Triangulation

22. GENOME EDITING TECHNOLOGIES MARKET, BY TYPE OF THERAPY

  • 22.1. Chapter Overview
  • 22.2. Key Assumptions and Methodology
  • 22.3. Genome Editing Technologies Market: Distribution by Type of Therapy
    • 22.3.1. Genome Editing Technologies Market for Cell Therapies: Forecasted Estimates, till 2035
    • 22.3.2. Genome Editing Technologies Market for Gene Therapies: Forecasted Estimates, till 2035
    • 22.3.3. Genome Editing Technologies Market for Other Therapies: Forecasted Estimates, till 2035
  • 22.4. Data Triangulation

23. GENOME EDITING TECHNOLOGIES MARKET, BY APPLICATION AREA

  • 23.1. Chapter Overview
  • 23.2. Key Assumptions and Methodology
  • 23.3. Genome Editing Technologies Market: Distribution by Application Area
    • 23.3.1. Genome Editing Technologies Market for Drug Discovery and Development: Forecasted Estimates, till 2035
    • 23.3.2. Genome Editing Technologies Market for Diagnostics: Forecasted Estimates, till 2035
  • 23.4. Data Triangulation

24. GENOME EDITING TECHNOLOGIES MARKET, BY TYPE OF END USER

  • 24.1. Chapter Overview
  • 24.2. Key Assumptions and Methodology
  • 24.3. Genome Editing Technologies Market: Distribution by Type of End User
    • 24.3.1. Genome Editing Technologies Market for Pharmaceutical and Biotechnology Companies: Forecasted Estimates, till 2035
    • 24.3.2. Genome Editing Technologies Market for Academic and Research Institutes: Forecasted Estimates, till 2035
  • 24.4. Data Triangulation

25. GENOME EDITING TECHNOLOGIES MARKET, BY KEY GEOGRAPHICAL REGIONS

  • 25.1. Chapter Overview
  • 25.2. Key Assumptions and Methodology
  • 25.3. Genome Editing Technologies Market: Distribution by Key Geographical Regions
    • 25.3.1. Genome Editing Technologies Market in North America: Forecasted Estimates, till 2035
      • 25.3.1.1. Genome Editing Technologies Market in the US: Forecasted Estimates, till 2035
      • 25.3.1.2. Genome Editing Technologies Market in Canada: Forecasted Estimates, till 2035
    • 25.3.2. Genome Editing Technologies Market in Europe: Forecasted Estimates, till 2035
      • 25.3.2.1. Genome Editing Technologies Market in Germany: Forecasted Estimates, till 2035
      • 25.3.2.2. Genome Editing Technologies Market in France: Forecasted Estimates, till 2035
      • 25.3.2.3. Genome Editing Technologies Market in Ireland: Forecasted Estimates, till 2035
    • 25.3.3. Genome Editing Technologies Market in Asia-Pacific: Forecasted Estimates, till 2035
      • 25.3.3.1. Genome Editing Technologies Market in South Korea: Forecasted Estimates, till 2035
      • 25.3.3.2. Genome Editing Technologies Market in China: Forecasted Estimates, till 2035
      • 25.3.3.3. Genome Editing Technologies Market in Japan: Forecasted Estimates, till 2035
  • 25.4. Market Dynamics Assessment
    • 25.4.1. Penetration Growth (P-G) Matrix
  • 25.5. Data Triangulation

26. GENOME EDITING TECHNOLOGIES MARKET: LEADING INDUSTRY PLAYERS

  • 26.1. Chapter Overview
  • 26.2. Leading Industry Players

27. CONCLUDING INSIGHTS

28. EXECUTIVE INSIGHTS

29. APPENDIX 1: TABULATED DATA

30. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Tables

  • Table 7.1 List of Genome Editing Technologies
  • Table 7.2 Genome Editing Technologies: Information on Type of Gene Editing Technique
  • Table 7.3 Genome Editing Technologies: Information on Type of Gene Editing Approach
  • Table 7.4 Genome Editing Technologies: Information on Type of Gene Delivery Method
  • Table 7.5 Genome Editing Technologies: Information on Type of Gene Delivery Modality
  • Table 7.6 Genome Editing Technologies: Information on Highest Phase of Drug Development Supported
  • Table 7.7 Genome Editing Technologies: Information on Therapeutic Area
  • Table 7.8 Genome Editing Technologies: Information on Application Area
  • Table 7.9 Genome Editing Technologies: List of Technology Providers
  • Table 7.10 Genome Editing Technology Providers: Information on Operational Model
  • Table 7.11 Genome Editing Technology Providers: Information on Product Centric Model and Technology Centric Model
  • Table 8.1 Genome Editing Technologies Provided by Players Headquartered in North America
  • Table 8.2 Genome Editing Technologies Provided by Players Headquartered in Europe
  • Table 8.3 Genome Editing Technologies Provided by Players Headquartered in Asia-Pacific, Middle East and North Africa, and Latin America
  • Table 9.1 Genome Editing Technology Providers: List of Companies Profiled
  • Table 9.2 Arcturus Therapeutics: Company Overview
  • Table 9.3 Arcturus Therapeutics: Technology Portfolio
  • Table 9.4 Arcturus Therapeutics: Recent Developments and Future Outlook
  • Table 9.5 Arsenal Bio: Company Overview
  • Table 9.6 Arsenal Bio: Technology Portfolio
  • Table 9.7 Arsenal Bio: Recent Developments and Future Outlook
  • Table 9.8 Beam Therapeutics: Company Overview
  • Table 9.9 Beam Therapeutics: Technology Portfolio
  • Table 9.10 Beam Therapeutics: Recent Developments and Future Outlook
  • Table 9.11 Caribou Biosciences: Company Overview
  • Table 9.12 Caribou Biosciences: Technology Portfolio
  • Table 9.13 Caribou Biosciences: Recent Developments and Future Outlook
  • Table 9.14 Century Therapeutics: Company Overview
  • Table 9.15 Century Therapeutics: Technology Portfolio
  • Table 9.16 Century Therapeutics: Recent Developments and Future Outlook
  • Table 9.17 CRISPR Therapeutics: Company Overview
  • Table 9.18 CRISPR Therapeutics: Technology Portfolio
  • Table 9.19 CRISPR Therapeutics: Recent Developments and Future Outlook
  • Table 9.20 Editas Medicine: Company Overview
  • Table 9.21 Editas Medicine: Technology Portfolio
  • Table 9.22 Editas Medicine: Recent Developments and Future Outlook
  • Table 9.23 Intellia Therapeutics: Company Overview
  • Table 9.24 Intellia Therapeutics: Technology Portfolio
  • Table 9.25 Intellia Therapeutics: Recent Developments and Future Outlook
  • Table 9.26 Prime Medicine: Company Overview
  • Table 9.27 Prime Medicine: Technology Portfolio
  • Table 9.28 Prime Medicine: Recent Developments and Future Outlook
  • Table 9.29 Vor Biopharma: Company Overview
  • Table 9.30 Vor Biopharma: Technology Portfolio
  • Table 9.31 Vor Biopharma: Recent Developments and Future Outlook
  • Table 10.1 Genome Editing Technology Providers: List of Companies Profiled
  • Table 10.2 Avectas: Company Overview
  • Table 10.3 Avectas: Technology Portfolio
  • Table 10.4 Bio-Sourcing: Company Overview
  • Table 10.5 Bio-Sourcing: Technology Portfolio
  • Table 10.6 Flash BioSolutions: Company Overview
  • Table 10.7 Flash BioSolutions: Technology Portfolio
  • Table 10.8 NTrans Technologies: Company Overview
  • Table 10.9 NTrans Technologies: Technology Portfolio
  • Table 10.10 OXGENE: Company Overview
  • Table 10.11 OXGENE: Technology Portfolio
  • Table 10.12 Revvity: Company Overview
  • Table 10.13 Revvity: Technology Portfolio
  • Table 11.1 Genome Editing Technology Providers: List of Companies Profiled
  • Table 11.2 Edigene: Company Overview
  • Table 11.3 Edigene: Technology Portfolio
  • Table 11.4 Fortgen: Company Overview
  • Table 11.5 Fortgen: Technology Portfolio
  • Table 11.6 G+FLAS Life Sciences: Company Overview
  • Table 11.7 G+FLAS Life Sciences: Technology Portfolio
  • Table 11.8 TargetGene Biotechnologies: Company Overview
  • Table 11.9 TargetGene Biotechnologies: Technology Portfolio
  • Table 12.1 Genome Editing Market: List of Partnerships and Collaborations
  • Table 12.2 Technology Licensing / Integration Agreements: Information on Purpose of Partnership
  • Table 12.3 Partnerships and Collaborations: Information on Type of Agreement
  • Table 13.1 Patent Analysis: Top CPC Sections
  • Table 13.2 Patent Analysis: Top CPC Symbols
  • Table 13.3 Patent Analysis: Top CPC Codes
  • Table 13.4 Patent Analysis: Summary of Benchmarking Analysis
  • Table 13.5 Patent Analysis: Categorization based on Weighted Valuation Scores
  • Table 13.6 Patent Portfolio: List of Leading Patents (by Highest Relative Valuation)
  • Table 14.1 Genome Editing Market: List of Funding and Investments
  • Table 16.1 Genome Editing Technologies: Average Upfront Payment and Average Milestone Payment, 2018-2024 (USD Million)
  • Table 16.2 Licensing Deals: Tranches of Milestone Payments
  • Table 26.1 Leading Industry Players: Based on General Market Understanding
  • Table 26.2 Leading Industry Players: Based on Funding Amount Invested (USD Million)
  • Table 26.3 Leading Industry Players: Based on Number of Technology Licensing / Integration Deals
  • Table 28.1 Prorenata Biotech: Company Snapshot
  • Table 29.1 Genome Editing Technologies: Distribution by Type of Gene Editing Technique
  • Table 29.2 Genome Editing Technologies: Distribution by Type of Gene Editing Approach
  • Table 29.3 Genome Editing Technologies: Distribution by Type of Gene Delivery Method
  • Table 29.4 Genome Editing Technologies: Distribution by Type of Gene Delivery Modality
  • Table 29.5 Genome Editing Technologies: Distribution by Highest Phase of Drug Development Supported
  • Table 29.6 Genome Editing Technologies: Distribution by Therapeutic Area
  • Table 29.7 Genome Editing Technologies: Distribution by Application Area
  • Table 29.8 Genome Editing Technology Providers: Distribution by Year of Establishment
  • Table 29.9 Genome Editing Technology Providers: Distribution by Company Size
  • Table 29.10 Genome Editing Technology Providers: Distribution by Location of Headquarters
  • Table 29.11 Genome Editing Technology Providers: Distribution by Company Size and Location of Headquarters
  • Table 29.12 Most Active Players: Distribution by Number of Technologies
  • Table 29.13 Genome Editing Technology Providers: Distribution by Operational Model
  • Table 29.14 Genome Editing Technology Providers: Distribution by Product Centric Model
  • Table 29.15 Genome Editing Technology Providers: Distribution by Technology Centric Model
  • Table 29.16 Arcturus Therapeutics: Annual Revenues, Since FY 2021 (USD Million)
  • Table 29.17 Beam Therapeutics: Annual Revenues, Since FY 2021 (USD Million)
  • Table 29.18 Caribou Biosciences: Annual Revenues, Since FY 2021 (USD Million)
  • Table 29.19 Century Therapeutics: Annual Revenues, Since FY 2022 (USD Million)
  • Table 29.20 CRISPR Therapeutics: Annual Revenues, Since FY 2021 (USD Million)
  • Table 29.21 Editas Medicine: Annual Revenues, Since FY 2021 (USD Million)
  • Table 29.22 Intellia Therapeutics: Annual Revenues, Since FY 2021 (USD Million)
  • Table 29.23 Partnerships and Collaborations: Cumulative Year-wise Trend
  • Table 29.24 Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 29.25 Partnerships and Collaborations: Distribution by Year and Type of Partnership
  • Table 29.26 Technology Licensing Agreements / Technology Integration Agreements: Distribution by Purpose of Partnership
  • Table 29.27 Partnerships and Collaborations: Distribution by Type of Partner
  • Table 29.28 Partnerships and Collaborations: Distribution by Location of Headquarters of Partner
  • Table 29.29 Most Active Players: Distribution by Number of Partnerships
  • Table 29.30 Partnership and Collaborations: Local and International Agreements
  • Table 29.31 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
  • Table 29.32 Patent Analysis: Distribution by Type of Patent
  • Table 29.33 Patent Analysis: Distribution by Patent Application Year
  • Table 29.34 Patent Analysis: Distribution by Patent Publication Year
  • Table 29.35 Patent Analysis: Distribution by Type of Patents and Publication Year
  • Table 29.36 Patent Analysis: Distribution by Patent Jurisdiction
  • Table 29.37 Patent Analysis: Cumulative Year-wise Trend by Type of Applicant
  • Table 29.38 Leading Industry Players: Distribution by Number of Patents
  • Table 29.39 Leading Non-Industry Players: Distribution by Number of Patents
  • Table 29.40 Leading Individual Assignees: Distribution by Number of Patents
  • Table 29.41 Patent Analysis: Distribution by Patent Age
  • Table 29.42 Genome editing: Patent Valuation
  • Table 29.43 Funding and Investment Analysis: Cumulative Year-wise Trend
  • Table 29.44 Funding and Investment Analysis: Cumulative Year-wise Trend of Amount Invested (USD Million)
  • Table 29.45 Funding and Investment Analysis: Distribution of Funding Instances by Type of Funding
  • Table 29.46 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
  • Table 29.47 Funding and Investment Analysis: Distribution by Year and Type of Funding
  • Table 29.48 Funding and Investments: Distribution of Funding Instances by Geography
  • Table 29.49 Most Active Players: Distribution by Amount Invested and Number of Funding Instances
  • Table 29.50 Leading Investors: Distribution by Number of Funding Instances
  • Table 29.51 Global Genome Editing Technologies Market, Forecasted Estimates, till 2035 (USD Billion)
  • Table 29.52 Global Genome Editing Technologies Market, Forecasted Estimates, till 2035: Conservative Scenario (USD Billion)
  • Table 29.53 Global Genome Editing Technologies Market, Forecasted Estimates, till 2035: Optimistic Scenario (USD Billion)
  • Table 29.54 Genome Editing Technologies Market: Distribution by Type of Payment Method Employed
  • Table 29.55 Genome Editing Technologies Market for Milestone Payments: Forecasted Estimates, till 2035 (USD Million)
  • Table 29.56 Genome Editing Technologies Market for Upfront Payments: Forecasted Estimates, till 2035 (USD Million)
  • Table 29.57 Genome Editing Technologies Market: Distribution by Type of Gene Editing Technique
  • Table 29.58 Genome Editing Technologies Market for CRISPR-Cas System: Forecasted Estimates, till 2035 (USD Million)
  • Table 29.59 Genome Editing Technologies Market for TALENs: Forecasted Estimates, till 2035 (USD Million)
  • Table 29.60 Genome Editing Technologies Market for Meganucleases: Forecasted Estimates, till 2035 (USD Million)
  • Table 29.61 Genome Editing Technologies Market for ZFNs: Forecasted Estimates, till 2035 (USD Million)
  • Table 29.62 Genome Editing Technologies Market for Other Techniques: Forecasted Estimates, till 2035 (USD Million)
  • Table 29.63 Genome Editing Technologies Market: Distribution by Type of Gene Editing Approach
  • Table 29.64 Genome Editing Technologies Market for Gene Knock-Out: Forecasted Estimates, till 2035 (USD Million)
  • Table 29.65 Genome Editing Technologies Market for Gene Knock-In: Forecasted Estimates, till 2035 (USD Million)
  • Table 29.66 Genome Editing Technologies Market: Distribution by Type of Gene Delivery Method
  • Table 29.67 Genome Editing Technologies Market for Ex vivo: Forecasted Estimates, till 2035 (USD Million)
  • Table 29.68 Genome Editing Technologies Market for In vivo: Forecasted Estimates, till 2035 (USD Million)
  • Table 29.69 Genome Editing Technologies Market: Distribution by Type of Gene Delivery Modality
  • Table 29.70 Genome Editing Technologies Market for Viral Vectors: Forecasted Estimates, till 2035 (USD Million)
  • Table 29.71 Genome Editing Technologies Market for Non-Viral Vectors: Forecasted Estimates, till 2035 (USD Million)
  • Table 29.72 Genome Editing Technologies Market: Distribution by Type of Therapy
  • Table 29.73 Genome Editing Technologies Market for Cell Therapies: Forecasted Estimates, till 2035 (USD Million)
  • Table 29.74 Genome Editing Technologies Market for Gene Therapies: Forecasted Estimates, till 2035 (USD Million)
  • Table 29.75 Genome Editing Technologies Market for Other Therapies: Forecasted Estimates, till 2035 (USD Million)
  • Table 29.76 Genome Editing Technologies Market: Distribution by Application Area
  • Table 29.77 Genome Editing Technologies Market for Drug Discovery and Development: Forecasted Estimates, till 2035 (USD Million)
  • Table 29.78 Genome Editing Technologies Market for Diagnostics: Forecasted Estimates, till 2035 (USD Million)
  • Table 29.79 Genome Editing Technologies Market: Distribution by Type of End-User
  • Table 29.80 Genome Editing Technologies Market for Pharmaceutical and Biotechnology Companies: Forecasted Estimates, till 2035 (USD Million)
  • Table 29.81 Genome Editing Technologies Market for Academic and Research Institutes: Forecasted Estimates, till 2035 (USD Million)
  • Table 29.82 Genome Editing Technologies Market: Distribution by Geographical Regions
  • Table 29.83 Genome Editing Technologies Market in North America: Forecasted Estimates, till 2035 (USD Million)
  • Table 29.84 Genome Editing Technologies Market in the US: Forecasted Estimates, till 2035 (USD Million)
  • Table 29.85 Genome Editing Technologies Market in Canada: Forecasted Estimates, till 2035 (USD Million)
  • Table 29.86 Genome Editing Technologies Market in Europe: Forecasted Estimates till 2035 (USD Million)
  • Table 29.87 Genome Editing Technologies Market in Germany: Forecasted Estimates till 2035 (USD Million)
  • Table 29.88 Genome Editing Technologies Market in France: Forecasted Estimates till 2035 (USD Million)
  • Table 29.89 Genome Editing Technologies Market in Ireland: Forecasted Estimates till 2035 (USD Million)
  • Table 29.90 Genome Editing Technologies Market in Asia-Pacific: Forecasted Estimates, till 2035 (USD Million)
  • Table 29.91 Genome Editing Technologies Market in South Korea: Forecasted Estimates, till 2035 (USD Million)
  • Table 29.92 Genome Editing Technologies Market in China: Forecasted Estimates, till 2035 (USD Million)
  • Table 29.93 Genome Editing Technologies Market in Japan: Forecasted Estimates, till 2035 (USD Million)

List of Figures

  • Figure 2.1 Research Methodology: Project Methodology
  • Figure 2.2 Research Methodology: Data Sources for Secondary Research
  • Figure 2.3 Research Methodology: Robust Quality Control
  • Figure 3.1 Market Dynamics: Forecast Methodology
  • Figure 3.2 Market Dynamics: Key Market Segmentation
  • Figure 4.1 Lessons Learnt from Past Recessions
  • Figure 5.1 Executive Summary: Genome Editing Technology Landscape
  • Figure 5.2 Executive Summary: Recent Trends Analysis
  • Figure 5.3 Executive Summary: Market Forecast and Opportunity Analysis
  • Figure 6.1 Genome Editing: Milestones Achieved in Gene Editing Domain
  • Figure 6.2 Types of Gene Editing Technologies
  • Figure 6.3 CRISPR / Cas System: Mechanism of Action
  • Figure 6.4 TALENs: Mechanism of Action
  • Figure 6.5 ZFNs: Mechanism of Action
  • Figure 6.6 Meganucleases / Homing Endonucleases: Mechanism of Action
  • Figure 6.7 Applications of Gene Editing Technologies
  • Figure 7.1 Genome Editing Technologies: Distribution by Type of Gene Editing Technique
  • Figure 7.2 Genome Editing Technologies: Distribution by Type of Gene Editing Approach
  • Figure 7.3 Genome Editing Technologies: Distribution by Type of Gene Delivery Method
  • Figure 7.4 Genome Editing Technologies: Distribution by Type of Gene Delivery Modality
  • Figure 7.5 Genome Editing Technologies: Distribution by Highest Phase of Drug Development Supported
  • Figure 7.6 Genome Editing Technologies: Distribution by Therapeutic Area
  • Figure 7.7 Genome Editing Technologies: Distribution by Application Area
  • Figure 7.8 Genome Editing Technology Providers: Distribution by Year of Establishment
  • Figure 7.9 Genome Editing Technology Providers: Distribution by Company Size
  • Figure 7.10 Genome Editing Technology Providers: Distribution by Location of Headquarters
  • Figure 7.11 Genome Editing Technology Providers: Distribution by Company Size and Location of Headquarters
  • Figure 7.12 Most Active Players: Distribution by Number of Technologies
  • Figure 7.13 Genome Editing Technology Providers: Distribution by Operational Model
  • Figure 7.14 Genome Editing Technology Providers: Distribution by Product Centric Model
  • Figure 7.15 Genome Editing Technology Providers: Distribution by Technology Centric Model
  • Figure 8.1 Genome Editing Technologies Developed by Players Headquartered in North America
  • Figure 8.2 Genome Editing Technologies Developed by Players Headquartered in Europe
  • Figure 8.3 Genome Editing Technologies Developed by Players Headquartered in Asia-Pacific, Middle East and North Africa, and Latin America
  • Figure 9.1 Arcturus Therapeutics: Annual Revenues, Since FY 2021 (USD Million)
  • Figure 9.2 Beam Therapeutics: Annual Revenues, Since FY 2021 (USD Million)
  • Figure 9.3 Caribou Biosciences: Annual Revenues, Since FY 2021 (USD Million)
  • Figure 9.4 Century Therapeutics: Annual Revenues, Since FY 2022 (USD Million)
  • Figure 9.5 CRISPR Therapeutics: Annual Revenues, Since FY 2021 (USD Million)
  • Figure 9.6 Editas Medicine: Annual Revenues, Since FY 2021 (USD Million)
  • Figure 9.7 Intellia Therapeutics: Annual Revenues, Since FY 2021 (USD Million)
  • Figure 12.1 Partnerships and Collaborations: Cumulative Year-wise Trend
  • Figure 12.2 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 12.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
  • Figure 12.4 Technology Licensing Agreements / Technology Integration Agreements: Distribution by Purpose of Partnership
  • Figure 12.5 Partnerships and Collaborations: Distribution by Type of Partner
  • Figure 12.6 Partnerships and Collaborations: Distribution by Location of Headquarters of Partner
  • Figure 12.7 Most Active Players: Distribution by Number of Partnerships
  • Figure 12.8 Partnerships and Collaborations: Local and International Agreements
  • Figure 12.9 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
  • Figure 13.1 Patent Analysis: Distribution by Type of Patent
  • Figure 13.2 Patent Analysis: Distribution by Patent Application Year
  • Figure 13.3 Patent Analysis: Distribution by Patent Publication Year
  • Figure 13.4 Patent Analysis: Distribution by Type of Patent and Publication Year
  • Figure 13.5 Patent Analysis: Distribution by Patent Jurisdiction
  • Figure 13.6 Patent Analysis: Distribution by CPC Symbols
  • Figure 13.7 Patent Analysis: Cumulative Year-wise Trend by Type of Applicant
  • Figure 13.8 Leading Industry Players: Distribution by Number of Patents
  • Figure 13.9 Leading Non-Industry Players: Distribution by Number of Patents
  • Figure 13.10 Leading Individual Assignees: Distribution by Number of Patents
  • Figure 13.11 Patent Benchmarking Analysis: Distribution of Patent Characteristics (CPC Codes) by Leading Industry Players
  • Figure 13.12 Patent Benchmarking Analysis: Distribution of Leading Industry Players by Patent Characteristics (CPC Codes)
  • Figure 13.13 Patent Analysis: Distribution by Patent Age
  • Figure 13.14 Genome editing: Patent Valuation
  • Figure 14.1 Funding and Investment Analysis: Cumulative Year-wise Trend
  • Figure 14.2 Funding and Investment Analysis: Cumulative Year-wise Trend of Amount Invested (USD Million)
  • Figure 14.3 Funding and Investment Analysis: Distribution of Funding Instances by Type of Funding
  • Figure 14.4 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
  • Figure 14.5 Funding and Investment Analysis: Distribution by Year and Type of Funding
  • Figure 14.6 Funding and Investments: Distribution of Funding Instances by Geography
  • Figure 14.7 Most Active Players: Distribution by Amount Invested and Number of Funding Instances
  • Figure 14.8 Leading Investors: Distribution by Number of Funding Instances
  • Figure 14.9 Funding and Investment Analysis: Summary of Investments
  • Figure 16.1 Licensing Agreements: Distribution of Financial Components
  • Figure 16.2 Licensing Agreements: Illustrative Scenario Based Opportunity Estimation
  • Figure 16.3 Global Genome Editing Technologies Market, Forecasted Estimates, till 2035 (USD Billion)
  • Figure 16.4 Global Genome Editing Technologies Market, Forecasted Estimates, till 2035: Conservative Scenario (USD Billion)
  • Figure 16.5 Global Genome Editing Technologies Market, Forecasted Estimates, till 2035: Optimistic Scenario (USD Billion)
  • Figure 17.1 Genome Editing Technologies Market: Distribution by Type of Payment Method Employed
  • Figure 17.2 Genome Editing Technologies Market for Milestone Payments: Forecasted Estimates, till 2035 (USD Million)
  • Figure 17.3 Genome Editing Technologies Market for Upfront Payments: Forecasted Estimates, till 2035 (USD Million)
  • Figure 18.1 Genome Editing Technologies Market: Distribution by Type of Gene Editing Technique
  • Figure 18.2 Genome Editing Technologies Market for CRISPR-Cas System: Forecasted Estimates, till 2035 (USD Million)
  • Figure 18.3 Genome Editing Technologies Market for TALENs: Forecasted Estimates, till 2035 (USD Million)
  • Figure 18.4 Genome Editing Technologies Market for Meganucleases: Forecasted Estimates, till 2035 (USD Million)
  • Figure 18.5 Genome Editing Technologies Market for ZFNs: Forecasted Estimates, till 2035 (USD Million)
  • Figure 18.6 Genome Editing Technologies Market for Other Techniques: Forecasted Estimates, till 2035 (USD Million)
  • Figure 19.1 Genome Editing Technologies Market: Distribution by Type of Gene Editing Approach
  • Figure 19.2 Genome Editing Technologies Market for Gene Knock-out: Forecasted Estimates, till 2035 (USD Million)
  • Figure 19.3 Genome Editing Technologies Market for Gene Knock-in: Forecasted Estimates, till 2035 (USD Million)
  • Figure 20.1 Genome Editing Technologies Market: Distribution by Type of Gene Delivery Method
  • Figure 20.2 Genome Editing Technologies Market for Ex vivo: Forecasted Estimates, till 2035 (USD Million)
  • Figure 20.3 Genome Editing Technologies Market for In vivo: Forecasted Estimates, till 2035 (USD Million)
  • Figure 21.1 Genome Editing Technologies Market: Distribution by Type of Gene Delivery Modality
  • Figure 21.2 Genome Editing Technologies Market for Viral Vectors: Forecasted Estimates, till 2035 (USD Million)
  • Figure 21.3 Genome Editing Technologies Market for Non-Viral Vectors: Forecasted Estimates, till 2035 (USD Million)
  • Figure 22.1 Genome Editing Technologies Market: Distribution by Type of Therapy
  • Figure 22.2 Genome Editing Technologies Market for Cell Therapies: Forecasted Estimates, till 2035 (USD Million)
  • Figure 22.3 Genome Editing Technologies Market for Gene Therapies: Forecasted Estimates, till 2035 (USD Million)
  • Figure 22.4 Genome Editing Technologies Market for Other Therapies: Forecasted Estimates, till 2035 (USD Million)
  • Figure 23.1 Genome Editing Technologies Market: Distribution by Application Area
  • Figure 23.2 Genome Editing Technologies Market for Drug Discovery and Development: Forecasted Estimates, till 2035 (USD Million)
  • Figure 23.3 Genome Editing Technologies Market for Diagnostics: Forecasted Estimates, till 2035 (USD Million)
  • Figure 24.1 Genome Editing Technologies Market: Distribution by Type of End User
  • Figure 24.2 Genome Editing Technologies Market for Pharmaceutical and Biotechnology Companies: Forecasted Estimates, till 2035 (USD Million)
  • Figure 24.3 Genome Editing Technologies Market for Academic and Research Institutes: Forecasted Estimates, till 2035 (USD Million)
  • Figure 25.1 Genome Editing Technologies Market: Distribution by Geographical Regions
  • Figure 25.2 Genome Editing Technologies Market in North America: Forecasted Estimates, till 2035 (USD Million)
  • Figure 25.3 Genome Editing Technologies Market in the US: Forecasted Estimates, till 2035 (USD Million)
  • Figure 25.4 Genome Editing Technologies Market in Canada: Forecasted Estimates, till 2035 (USD Million)
  • Figure 25.5 Genome Editing Technologies Market in Europe: Forecasted Estimates, till 2035 (USD Million)
  • Figure 25.6 Genome Editing Technologies Market in Germany: Forecasted Estimates, till 2035 (USD Million)
  • Figure 25.7 Genome Editing Technologies Market in France: Forecasted Estimates, till 2035 (USD Million)
  • Figure 25.8 Genome Editing Technologies Market in Ireland: Forecasted Estimates, till 2035 (USD Million)
  • Figure 25.9 Genome Editing Technologies Market in Asia-Pacific: Forecasted Estimates, till 2035 (USD Million)
  • Figure 25.10 Genome Editing Technologies Market in South Korea: Forecasted Estimates, till 2035 (USD Million)
  • Figure 25.11 Genome Editing Technologies Market in China: Forecasted Estimates, till 2035 (USD Million)
  • Figure 25.12 Genome Editing Technologies Market in Japan: Forecasted Estimates, till 2035 (USD Million)
  • Figure 25.13 Penetration Growth (P-G) Matrix: Key Geographical Regions
  • Figure 26.1 Genome Editing Technologies Market for Leading Industry Players (USD Million)
  • Figure 27.1 Concluding Remarks: Technology Landscape
  • Figure 27.2 Concluding Remarks: Partnerships and Collaborations
  • Figure 27.3 Concluding Remarks: Patent Analysis
  • Figure 27.4 Concluding Remarks: Funding and Investments Analysis
  • Figure 27.5 Concluding Remarks: Market Forecast and Opportunity Analysis